Peptic Ulcers - Pipeline Review, H1 2020

June 2020 | 65 pages | ID: PE417FCD712EN
Global Markets Direct

Abstracts

Peptic Ulcers - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peptic Ulcers - Pipeline Review, H1 2020, provides an overview of the Peptic Ulcers (Gastrointestinal) pipeline landscape.
Peptic ulcers are open sores that develop on the inside lining of esophagus, stomach and the upper portion of small intestine. Symptoms include nausea or vomiting, unexplained weight loss, appetite changes and abdominal pain. Risk factors include smoking and alcoholism. Treatment includes antibiotic, acid blockers, antacids and proton pump inhibitors.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Peptic Ulcers - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Peptic Ulcers (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Peptic Ulcers (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Peptic Ulcers and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 3, 3, 1, 3, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Peptic Ulcers (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Peptic Ulcers (Gastrointestinal).
• The pipeline guide reviews pipeline therapeutics for Peptic Ulcers (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Peptic Ulcers (Gastrointestinal) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Peptic Ulcers (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Peptic Ulcers (Gastrointestinal)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Peptic Ulcers (Gastrointestinal).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Peptic Ulcers (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Peptic Ulcers - Overview
Peptic Ulcers - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Peptic Ulcers - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Peptic Ulcers - Companies Involved in Therapeutics Development
Axsome Therapeutics Inc
Balto Therapeutics
CalyGene Biotechnology Inc
Chong Kun Dang Pharmaceutical Corp
Daewoong Pharmaceutical Co Ltd
FortuneRock (China) Ltd
Hunan Mingrui Pharmaceutical Co Ltd
Hunan Sailong Pharmaceutical Co Ltd
Ilyang Pharmaceutical Co Ltd
Jiangsu Aosaikang Pharmaceutical Co Ltd
PharmaKing Co Ltd
RaQualia Pharma Inc
Sama Pharm Co Ltd
Wooridul Pharmaceutical Ltd
XuanZhu Pharma Co Ltd
Peptic Ulcers - Drug Profiles
(esomeprazole + sodium bicarbonate) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(meloxicam + esomeprazole) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CG-20043 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dexlansoprazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dexlansoprazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fexuprazan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
glycopyrrolate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ilaprazole DR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KBP-3571 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pantoprazole sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PMKS-005 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rabeprazole sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SA-15001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SFR-9X0123 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit COX-2 for Gastric Ulcers, Inflammation and Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tegoprazan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
WRDN-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptic Ulcers - Dormant Projects
Peptic Ulcers - Discontinued Products
Peptic Ulcers - Product Development Milestones
Featured News & Press Releases
Feb 13, 2020: Sihuan Pharmaceutical Holdings Group: Commencement of phase III clinical trial in the PRC for self-developed innovative patented drug Anaprazole Sodium
Apr 25, 2019: Sihuan Pharm's innovative digestive system drug Anaprazole Sodium achieved early completion of patient recruitment for phase II clinical trial in China
Jul 17, 2013: Sihuan Pharmaceutical Secures SFDA Approval for Anaprazole Sodium Category 1.1 New Drug Clinical Studies
Jul 27, 2011: Ilyang Pharmaceuticals Obtains Patent For Ilaprazole
Mar 01, 2010: AstraZeneca Provides An Update On The Status Of Its Arrangements With Merck
Mar 01, 2010: AstraZeneca Provides An Update On The Status Of Its Arrangements With Merck
Jan 07, 2010: AstraZeneca Reaches Agreements With Teva Pharmaceuticals Regarding Nexium And Prilosec US Patent Litigations
Jan 07, 2010: AstraZeneca Reaches Agreements With Teva Pharmaceuticals Regarding Nexium And Prilosec US Patent Litigations
Apr 15, 2008: AstraZeneca Settles US Nexium Patent Litigation with Ranbaxy
Apr 15, 2008: AstraZeneca Settles US Nexium Patent Litigation with Ranbaxy
Feb 28, 2008: AstraZeneca Provides An Update on the Status of its Arrangements With Merck & Co., Inc.
Feb 28, 2008: AstraZeneca Provides An Update on the Status of its Arrangements With Merck & Co., Inc.
Dec 10, 2007: FDA Concludes There Is No Increased Risk Of Cardiac Events For Patients Treated With Omeprazole And NEXIUM (Esomeprazole Magnesium)
Dec 10, 2007: FDA Concludes There Is No Increased Risk Of Cardiac Events For Patients Treated With Omeprazole And NEXIUM (Esomeprazole Magnesium)
Jun 01, 2007: AstraZeneca’s Prilosec Patents Upheld By Court
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Peptic Ulcers, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Peptic Ulcers - Pipeline by Axsome Therapeutics Inc, H1 2020
Peptic Ulcers - Pipeline by Balto Therapeutics, H1 2020
Peptic Ulcers - Pipeline by CalyGene Biotechnology Inc, H1 2020
Peptic Ulcers - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2020
Peptic Ulcers - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2020
Peptic Ulcers - Pipeline by FortuneRock (China) Ltd, H1 2020
Peptic Ulcers - Pipeline by Hunan Mingrui Pharmaceutical Co Ltd, H1 2020
Peptic Ulcers - Pipeline by Hunan Sailong Pharmaceutical Co Ltd, H1 2020
Peptic Ulcers - Pipeline by Ilyang Pharmaceutical Co Ltd, H1 2020
Peptic Ulcers - Pipeline by Jiangsu Aosaikang Pharmaceutical Co Ltd, H1 2020
Peptic Ulcers - Pipeline by PharmaKing Co Ltd, H1 2020
Peptic Ulcers - Pipeline by RaQualia Pharma Inc, H1 2020
Peptic Ulcers - Pipeline by Sama Pharm Co Ltd, H1 2020
Peptic Ulcers - Pipeline by Wooridul Pharmaceutical Ltd, H1 2020
Peptic Ulcers - Pipeline by XuanZhu Pharma Co Ltd, H1 2020
Peptic Ulcers - Dormant Projects, H1 2020
Peptic Ulcers - Dormant Projects, H1 2020 (Contd..1), H1 2020
Peptic Ulcers - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Peptic Ulcers, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

Axsome Therapeutics Inc
Balto Therapeutics
CalyGene Biotechnology Inc
Chong Kun Dang Pharmaceutical Corp
Daewoong Pharmaceutical Co Ltd
FortuneRock (China) Ltd
Hunan Mingrui Pharmaceutical Co Ltd
Hunan Sailong Pharmaceutical Co Ltd
Ilyang Pharmaceutical Co Ltd
Jiangsu Aosaikang Pharmaceutical Co Ltd
PharmaKing Co Ltd
RaQualia Pharma Inc
Sama Pharm Co Ltd
Wooridul Pharmaceutical Ltd
XuanZhu Pharma Co Ltd